Barinthus Biotherapeutics PLC
BRNS1.300USD
-0.100-7.14%
Cierre 08/04, 16:00（ET）Cotizaciones retrasadas 15 min
52.44MCap. mercado
PérdidaP/E TTM
Más Datos de Barinthus Biotherapeutics PLC Compañía
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases and autoimmunity. Its pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells and guide them towards a healthy balance. It is focused on developing two key product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease.
Información de la empresa
Símbolo de cotizaciónBRNS
Nombre de la empresaBarinthus Biotherapeutics PLC
Fecha de salida a bolsaApr 30, 2021
Director ejecutivoMr. William J. (Bill) Enright
Número de empleados105
Tipo de seguridadDepository Receipt
Fin del año fiscalApr 30
DirecciónUnit 6-10, Zeus Building, Rutherford Avenue
CiudadDIDCOT
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited Kingdom
Código postalOX11 0DF
Teléfono441865818808
Sitio Webhttps://www.barinthusbio.com/
Símbolo de cotizaciónBRNS
Fecha de salida a bolsaApr 30, 2021
Director ejecutivoMr. William J. (Bill) Enright
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Geoffrey Lynn
Dr. Geoffrey Lynn
Chief Scientific Officer
Chief Scientific Officer
638.44K
--
Mr. Robin Wright
Mr. Robin Wright
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
48.26K
--
Dr. Pierre A. Morgon, Pharm.D.
Dr. Pierre A. Morgon, Pharm.D.
Non-Executive Independent Director
Non-Executive Independent Director
10.51K
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
3.00K
--
Dr. Joseph C. Scheeren
Dr. Joseph C. Scheeren
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. William J. (Bill) Enright
Mr. William J. (Bill) Enright
Chief Executive Officer, Principal Financial Officer, Director
Chief Executive Officer, Principal Financial Officer, Director
--
--
Ms. Karen T. Dawes
Ms. Karen T. Dawes
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Alex Hammacher
Dr. Alex Hammacher
Non-Executive Director
Non-Executive Director
--
--
Mr. Robin Wright
Mr. Robin Wright
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Alex Hammacher
Dr. Alex Hammacher
Non-Executive Director
Non-Executive Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Geoffrey Lynn
Dr. Geoffrey Lynn
Chief Scientific Officer
Chief Scientific Officer
638.44K
--
Mr. Robin Wright
Mr. Robin Wright
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
48.26K
--
Dr. Pierre A. Morgon, Pharm.D.
Dr. Pierre A. Morgon, Pharm.D.
Non-Executive Independent Director
Non-Executive Independent Director
10.51K
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
3.00K
--
Dr. Joseph C. Scheeren
Dr. Joseph C. Scheeren
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. William J. (Bill) Enright
Mr. William J. (Bill) Enright
Chief Executive Officer, Principal Financial Officer, Director
Chief Executive Officer, Principal Financial Officer, Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 4 de jul
Actualizado: vie., 4 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Oxford Science Enterprises PLC
21.81%
M&G Investment Management Ltd.
12.88%
Cawood (Frank Wayne)
8.39%
Alphabet, Inc.
3.75%
HSG Holding Ltd.
3.52%
Other
49.64%
Accionistas
Accionistas
Proporción
Oxford Science Enterprises PLC
21.81%
M&G Investment Management Ltd.
12.88%
Cawood (Frank Wayne)
8.39%
Alphabet, Inc.
3.75%
HSG Holding Ltd.
3.52%
Other
49.64%
Tipos de accionistas
Accionistas
Proporción
Venture Capital
25.56%
Investment Advisor
18.09%
Individual Investor
13.54%
Corporation
0.92%
Investment Advisor/Hedge Fund
0.53%
Endowment Fund
0.30%
Hedge Fund
0.15%
Research Firm
0.04%
Other
40.87%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
40
23.85M
59.13%
+716.00K
2025Q1
41
23.85M
60.03%
+745.95K
2024Q4
40
24.08M
59.87%
+1.54M
2024Q3
37
20.03M
50.21%
-349.60K
2024Q2
38
20.26M
51.12%
-213.80K
2024Q1
38
20.04M
50.62%
-468.31K
2023Q4
42
19.97M
51.73%
-616.84K
2023Q3
45
19.96M
51.78%
-695.67K
2023Q2
52
20.10M
52.29%
-1.03M
2023Q1
51
20.44M
53.30%
-692.87K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Oxford Science Enterprises PLC
8.80M
21.81%
--
--
Apr 14, 2025
M&G Investment Management Ltd.
5.20M
12.88%
--
--
Mar 31, 2025
Cawood (Frank Wayne)
3.38M
8.39%
+1.04M
+44.47%
Dec 31, 2024
Alphabet, Inc.
1.51M
3.75%
--
--
Mar 31, 2025
HSG Holding Ltd.
1.42M
3.52%
--
--
Mar 31, 2025
Enright (William)
1.24M
3.08%
--
--
Apr 14, 2025
DC Funds, LP
642.20K
1.59%
--
--
Mar 31, 2025
Lynn (Geoffrey)
638.44K
1.58%
+638.44K
--
Dec 17, 2024
Gilead Sciences Inc
369.86K
0.92%
-250.50K
-40.38%
Mar 31, 2025
Johns Hopkins University
122.24K
0.3%
--
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
ActivePassive International Equity ETF
0%
ActivePassive International Equity ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
